



Financial Tear Sheet

Where the power of nature meets the logic of science for the betterment of health.

ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property. We then utilize our in-house chemistry, regulatory and safety consulting business units to commercialize the ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive patent protection. Our portfolio of ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene and; PUREENERGY®, a caffeine-pTeroPure® co-crystal. To learn more about ChromaDex, please visit www.chromadex.com.

ChromaDex Contact:

Andrew Johnson, Director of Investor Relations

949-419-0288

andrewj@chromadex.com

Stock Performance

CDXC (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$6.34
Change (%)	▲ 0.10 (1.60%)
Volume	313,406
52 Week Low	\$2.26
Market Cap	\$305,507,469
Rolling EPS	-0.15
PE Ratio	N/A
Shares Outstanding	48,187,298

Data as of 12/15/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Headlines & Events

Date	Title
12/14/17	Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure
12/08/17	Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer's Disease Research
12/04/17	The promoting mechanism of TRU NIAGEN™ to be featured at the American Academy of Anti-Aging Medicine World Congress

There are currently no events scheduled.

SEC Filings

Filing Date	Form
12/14/17	S-3
12/05/17	CT ORDER
11/29/17	D
11/21/17	SC 13D/A

Corporate Governance

Frank L. Jaksch Jr.	CEO
Steve R. Allen	Chairman
Jeff Baxter	Non-Executive Director
Steven A. Block	Non-Executive Director
Rob Fried	President and Chief Strategy Officer
Kurt Gustafson	Non-Executive Director
Tony Lau	Non-Executive Director
Steven D. Rubin	Non-Executive Director
Wendy Yu	Non-Executive Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	67	131.49	49.7	26,724,139
Mutual Fund	19	6.16	2.7	1,445,230
Insider *	4	2.58	1.5	801,798

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Champion River Ventures, Ltd.	6,500,937	12.1	731,707	11/21/17
Pioneer Step Holdings, Ltd.	4,333,960	8.1	487,805	11/21/17
Frost Phillip MD ET AL	3,404,521	6.3	-65,000	08/15/17
Brauser (Michael H)	2,933,220	5.5	3	05/25/17
Honig (Barry Charles)	2,409,312	4.5	-488,299	12/31/16
Black Sheep, FLP	2,075,052	3.9	0	05/25/17
The Vanguard Group, Inc.	978,990	1.8	85,049	09/30/17
Smithburg (William D)	640,000	1.2	640,000	06/06/16
Fried (Robert N)	595,985	1.1	10,000	08/15/17
Tieton Capital Management, LLC	590,702	1.1	-25,918	09/30/17